RBC Capital Maintains Outperform Rating on Nurix Therapeutics
RBC Capital maintained its $35 price target for Nurix Therapeutics; the target implies 57.9% upside from the Oct. 12 close of $22.16.
Story updates
03:04:33 PM UTC
SquawkNews
Nurix Therapeutics Price Target Cut to $35.00/Share From $36.00 by RBC Capital